RxDoctor Payments Data

Michael Remines, DO

Internal Medicine · Myrtle Beach, SCNPI 1205891942

Payments from drug & device makers

$4,553in general payments, 2019–2025

Across 265 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$834
  • AstraZeneca$515
  • AbbVie$435
  • Amgen$305
  • GSK$217
  • Takeda Pharmaceuticals U.S.A., Inc.$215
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,52199%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,553 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$56,742
Medicare patients
398
Services billed
3,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$88,152
JardianceEmpagliflozin64$73,043
MounjaroTirzepatide55$66,444
OzempicSemaglutide61$60,330
FarxigaDapagliflozin Propanediol30$39,750
RybelsusSemaglutide14$30,319
XareltoRivaroxaban24$24,173
Tresiba Flextouch U-100Insulin Degludec11$22,190
MyrbetriqMirabegron20$17,323
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$12,073
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,048
SynthroidLevothyroxine Sodium34$3,066
Atorvastatin Calcium209$2,567
Rosuvastatin Calcium210$2,411
Albuterol Sulfate HfaAlbuterol Sulfate70$2,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$834$90,65075 claims
PfizerEliquis$140$88,15288 claims
Boehringer IngelheimJardiance$204$73,04364 claims
Lilly USA, LLCMounjaro$88$66,44455 claims
AstraZenecaFarxiga$515$39,75030 claims
Johnson & JohnsonXarelto$11$24,17324 claims
Astellas Pharma US IncMyrbetriq$31$17,32320 claims
GSKTrelegy Ellipta$217$11,04812 claims
AbbVieSynthroid$435$3,06634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →